Hepatotoxicity by Drugs: The Most Common Implicated Agents

被引：180
作者：
Bjornsson, Einar S. [1 ,2 ]
机构：
[1] Univ Iceland, Natl Univ Hosp Iceland, Div Gastroenterol & Hepatol, Dept Internal Med, IS-108 Reykjavik, Iceland
[2] Univ Iceland, Fac Med, IS-108 Reykjavik, Iceland
来源：
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | 2016年 / 17卷 / 02期
关键词：
hepatotoxicity; drugs; drug-induced liver injury; idiosyncratic; INDUCED LIVER-INJURY; POPULATION; OUTCOMES; HEPATITIS; FEATURES;
D O I：
10.3390/ijms17020224
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Idiosyncratic drug-induced liver injury (DILI) is an underreported and underestimated adverse drug reaction. Information on the documented hepatotoxicity of drugs has recently been made available by a website that can be accessed in the public domain: LiverTox (http://livertox.nlm.nih.gov). According to critical analysis of the hepatotoxicity of drugs in LiverTox, 53% of drugs had at least one case report of convincing reports of liver injury. Only 48 drugs had more than 50 case reports of DILI. Amoxicillin-clavulanate is the most commonly implicated agent leading to DILI in the prospective series. In a recent prospective study, liver injury due to amoxicillin-clavulanate was found to occur in approximately one out of 2300 users. Drugs with the highest risk of DILI in this study were azathioprine and infliximab.
引用
收藏
页数：7
相关论文
共 21 条
  • [1] Important Elements for the Diagnosis of Drug-Induced Liver Injury
    Agarwal, Vijay K.
    McHutchison, John G.
    Hoofnagle, Jay H.
    [J]. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2010, 8 (05) : 463 - 470
  • [2] Rechallenge in drug-induced liver injury: the attractive hazard
    Andrade, Raul J.
    Robles, Mercedes
    Lucena, Maria Isabel
    [J]. EXPERT OPINION ON DRUG SAFETY, 2009, 8 (06) : 709 - 714
  • [3] Drug-induced liver injury:: An analysis of 461 incidences submitted to the Spanish Registry over a 10-year period
    Andrade, RJ
    Lucena, MI
    Fernández, MC
    Pelaez, G
    Pachkoria, K
    García-Ruiz, E
    García-Munoz, B
    González-Grande, R
    Pizarro, A
    Durán, JA
    Jiménez, M
    Rodrigo, L
    Romero-Gomez, M
    Navarro, JM
    Planas, R
    Costa, J
    Borras, A
    Soler, A
    Salmerón, J
    Martin-Vivaldi, R
    [J]. GASTROENTEROLOGY, 2005, 129 (02) : 512 - 521
  • [4] Outcome and prognostic markers in severe drug-induced liver disease
    Björnsson, E
    Olsson, R
    [J]. HEPATOLOGY, 2005, 42 (02) : 481 - 489
  • [5] Bjornsson E.S., 2015, HEPATOLOGY
  • [6] Discrepancies in Liver Disease Labeling in the Package Inserts of Commonly Prescribed Medications
    Bjornsson, Einar S.
    Jacobsen, Elin I.
    Einarsdottir, Rannveig
    Chalasani, Naga
    [J]. GASTROENTEROLOGY, 2015, 148 (02) : 269 - 273
  • [7] Incidence, Presentation, and Outcomes in Patients With Drug-Induced Liver Injury in the General Population of Iceland
    Bjornsson, Einar S.
    Bergmann, Ottar M.
    Bjornsson, Helgi K.
    Kvaran, Runar B.
    Olafsson, Sigurdur
    [J]. GASTROENTEROLOGY, 2013, 144 (07) : 1419 - U168
  • [8] Severe hepatitis in three AIDS patients treated with indinavir
    Brau, N
    Leaf, HL
    Wieczorek, RL
    Margolis, DM
    [J]. LANCET, 1997, 349 (9056) : 924 - 925
  • [9] Features and Outcomes of 899 Patients With Drug-Induced Liver Injury: The DILIN Prospective Study
    Chalasani, Naga
    Bonkovsky, Herbert L.
    Fontana, Robert
    Lee, William
    Stolz, Andrew
    Talwalkar, Jayant
    Reddy, K. Rajendar
    Watkins, Paul B.
    Navarro, Victor
    Barnhart, Huiman
    Gu, Jiezhun
    [J]. GASTROENTEROLOGY, 2015, 148 (07) : 1340 - +
  • [10] Causes, Clinical Features, and Outcomes From a Prospective Study of Drug-induced Liver Injury in the United States
    Chalasani, Naga
    Fontana, Robert J.
    Bonkovsky, Herbert L.
    Watkins, Paul B.
    Davern, Timothy
    Serrano, Jose
    Yang, Hongqiu
    Rochon, James
    [J]. GASTROENTEROLOGY, 2008, 135 (06) : 1924 - 1934
123